share_log
Reuters ·  May 15 08:38
Zyversa Therapeutics: Inflammasome Asc Inhibitor Ic 100's Preclinical Program Nearing Completion, Glp Toxicology Studies Expected to Begin H1-2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment